Virbac targets upper guidance range for Virbac stock

Published on 10/20/2026 at 13:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Virbac reported EUR 1.168 billion for nine months, up 7.90 percent at constant scope. Virbac stock costs EUR 335.75 on October 20, 2026.

Revenue growth sets the tone

Third-quarter revenue reached EUR 400 million on October 19, 2026.
Virbac targets the upper end of its 5.50 to 7.50 percent 2026 growth range.
Virbac stock trades at EUR 335.75 at 1:07 p.m. CEST at Lang & Schwarz on October 20, 2026.

Makrofoto von Glasfläschchen mit klarer Flüssigkeit und Tropfen — Makroaufnahme von Impfstofffläschchen zeigt Detailmaterial der Virbac S.A., FR0000031577, Branche Tiergesundheit intensiv, Illustration mit AI erstellt.

Virbac (ISIN FR0000031577) reported EUR 1,168 million in revenue for the first nine months of 2026, up 7.90 percent at constant exchange rates and scope. According to Yahoo Finance on October 19, 2026, the stronger third-quarter performance led the animal health group to target the upper end of its annual growth range.

Third-quarter revenue accelerates

Third-quarter revenue reached EUR 400 million, compared with EUR 364 million a year earlier. That equals 9.80 percent growth at actual exchange rates and 8.80 percent at constant exchange rates and scope, according to Yahoo Finance.

The nine-month increase was 5.90 percent at actual exchange rates, below the 7.90 percent constant-scope figure because of currency effects. The company also reported growth of 8.80 percent in companion animals and 7.00 percent in farm animals over the period.

Three milestones from 2026

On September 17, 2026, Virbac announced that first-half momentum of 7.40 percent supported a target for the upper end of its 5.50 to 7.50 percent 2026 revenue-growth range, as reported by Simply Wall St. On October 19, 2026, the third-quarter release put revenue at EUR 400 million. The latest event therefore adds a quantified acceleration to the existing guidance framework.

What does 7.90 percent growth change?

Virbac kept its 2026 revenue-growth range at 5.50 to 7.50 percent and positioned its nine-month result at the top of that corridor. The company also retains an adjusted recurring operating margin objective of 17.00 percent and expects cash generation of EUR 80 million after EUR 125 million of investment, according to Yahoo Finance. For investors, the key test is whether the stronger sales pace converts into the planned margin and cash profile.

Next reporting date January 19

Virbac lists fourth-quarter and full-year 2026 sales for January 19, 2027, after the market close, on its investor calendar.

Market value and trading level

Simply Wall St lists Virbac at a market capitalization of EUR 2.8 billion and a 52-week range of EUR 297.00 to EUR 389.50. The range places the current euro quote below the yearly high while the operating update supplies the more immediate business measure.

Virbac stock was trading intraday at EUR 335.75 at Lang & Schwarz on October 20, 2026, at 1:07 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Virbac stock.